Free Newsletter
Pfizer to add Wyeth directors to board
A regulatory filing made yesterday reveals more juicy details about the Pfizer-Wyeth deal: Pfizer will add two Wyeth directors to its board, the Associated Press reports, and if Wyeth backs out of the deal, it would have to pay a breakup fee of up to $2 billion. As you know, Pfizer's breakup fee is more than double that, at $4.5 billion. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: